Ilkka Julkunen
ilkka.julkunen@utu.fi +358 29 450 4507 +358 50 449 9721 Kiinamyllynkatu 10 Turku |
2 of 6
- The comprehensive SARS-CoV-2 ‘hijackome’ knowledge baseComparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variantsInactivation efficacy of H5N1 avian influenza virus by commonly used sample preparation reagents for safe laboratory practicesSerological Follow-Up Study Indicates High Seasonal Coronavirus Infection and Reinfection Rates in Early Childhood (2024)
- Cell DiscoveryNature CommunicationsJournal of Virological MethodsMicrobiology spectrum
- Virusinfektioiden immunologiaLong-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients (2024) Mikrobiologia, immunologia ja infektiosairaudet. Kirja 2, Immunologia Julkunen, Ilkka; Arstila, Petteri; Silvennoinen, Olli
- Virus-specific Dicer-substrate siRNA swarms inhibit SARS-CoV-2 infection in TMPRSS2-expressing Vero E6 cells (2024)
- Frontiers in microbiologyFrontiers in immunologyOpen Forum Infectious Diseases
- Coronavirus spike protein-specific antibodies indicate frequent infections and reinfections in infancy and among BNT162b2-vaccinated healthcare workers (2023)
- Scientific Reports
- COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs (2023)
- VaccineFrontiers in immunology
- Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2 (2023)
- Cell reports : methods
- Infectious viruses from transfected SARS-CoV-2 genomic RNAStrong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection (2023)
- Frontiers in Bioengineering and Biotechnology
- Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses (2023)
- Biomolecules
- Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine doseVaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination (2023)
- Frontiers in immunologyMicrobiology spectrum
- T cell immunity following COVID-19 vaccination in adult patients with primary antibody deficiency - a 22-month follow-up (2023)
- Frontiers in immunology
- VP24 matrix proteins of eight filoviruses downregulate innate immune response by inhibiting the interferon-induced pathway (2023)
- Journal of General Virology
- (2022)
- Filovirus VP24 Proteins Differentially Regulate RIG-I and MDA5-Dependent Type I and III Interferon Promoter Activation (2022)
- (2022)
- (2022)
- Frontiers in immunology
- Low pre-vaccination SARS-CoV-2 seroprevalence in Finnish health care workers: a prospective cohort study (2022)
- Infectious Diseases
- SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant (2022)
- (2022)
- (2022)
- (2022)
UTU Research Portal